Related Experiment Video
Updated: Oct 11, 2025
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
20.6K
Clinical Studies on Ultrafractionated Chemoradiation: A Systematic Review
Erica Scirocco1,2, Francesco Cellini3,4, Alice Zamagni1,2
1Radiation Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Frontiers in Oncology
|December 6, 2021
Summary
Low-dose fractionated radiotherapy (LDFRT) combined with chemotherapy shows promising results for advanced cancers. This review found improved tumor response and survival with manageable toxicity compared to chemotherapy alone.
Area of Science:
- Oncology
- Radiation Oncology
- Clinical Trials
Background:
- Preclinical data suggest efficacy for low-dose fractionated radiotherapy (LDFRT) and chemotherapy (CHT) combination.
- Limited clinical evidence exists for LDFRT plus concurrent CHT in advanced cancers.
Approach:
- Systematic literature search using PRISMA methodology on PubMed.
- Included studies combined LDFRT (< 1 Gy/fraction) with CHT.
- Analyzed tumor response, toxicity, and overall survival.
Key Points:
- Seven of eight studies showed higher tumor response rates with LDFRT-CHT versus CHT alone.
- Three of four studies reported improved survival with LDFRT-CHT.
- Toxicity was similar between LDFRT-CHT and CHT alone, with manageable adverse events.
Conclusions:
- No Level I evidence was found for LDFRT plus CHT.
- Most studies reported improved therapeutic outcomes and similar tolerability compared to CHT alone.
- Further research is warranted to establish definitive clinical impact.
